Opportunity timeline
In plain English
The Army wants to collaborate with partners on its Generative Unconstrained Intelligence Drug Engineering (GUIDE) program, which uses advanced computing and machine learning to develop medical countermeasures like antibodies, vaccines, and small molecule drugs. They are looking for organizations with technical expertise in medical countermeasure development to participate. Interested parties should email the listed contacts to request participation and demonstrate their technical relevance.
About this opportunity
W911SR-25-S-GUIDE Notice Type: Special Announcement Synopsis: This is a solicitation for parties interested in participating in projects sought by the The Joint Project Lead Chemical, Biological, Radiological, and Nuclear Defense Enabling Biotechnologies (JPL-CBRND-EB) (JPL EB). JPL EB has the mission to accelerate the delivery of medical countermeasures to the warfighter through the development and implementation of platform systems. Generative Unconstrained Intelligence Drug Engineering (GUIDE) is an integrated computational and experimental platform designed to accelerate medical countermeasure development. GUIDE harnesses the power of advanced simulation and machine learning to enable…
Standing opportunity — rolling deadline
Open long-term (listed until Oct 18, 2028). Check the posting for round or enrollment dates.
Related Opportunities

Illumina DRAGEN Tier 3 Throughput License and v4 Server

Emergent Drug Panel-Version 2 (EDP-V2) Kit

Medicinal Chemistry Support Program for Therapeutic Development (MCSP)

Medicinal Chemistry Support Program for Therapeutic Development (MCSP)

Health Advisory Committees Research and Support
Bid details are gathered and summarized automatically. Please verify details at the original source.
Ref No.
BS-3150CB

